New study to compare bone strength in hemophilia treatments
NCT ID NCT07582276
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study looks at bone health in 50 men aged 30-50 with severe hemophilia A who are on one of two long-term treatments: Efanesoctocog alfa or Emicizumab. The goal is to measure changes in bone mineral density over time to see if one treatment is better for bone health. Participants must have been on their current treatment for at least 3 months and plan to stay on it for 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.